Childhood Cancer Survivors at Higher Risk for New Cancers Even After 40

Article

While the risk of a new treatment-related cancer diagnosis after childhood is known, a new study now shows that this risk remains into the fifth and sixth decade of life.

While the increased risk of a new cancer diagnosis in survivors of childhood cancers is known, a new study now shows that this heightened risk persists into the fifth and sixth decade of life.

The study, published in the Journal of Clinical Oncology, is the first to extensively analyze cancer incidence among an aging childhood cancer survivors cohort. Compared with the general population, survivors in the study were found to have a twofold risk of being diagnosed with a second cancer after the age of 40.

Lucie M. Turcotte, MD, of the University of Minnesota Medical School in Minneapolis, and colleagues analyzed a cohort of 3,171 patients who were at least 40 years of age and took part in the Childhood Cancer Survivor Study (CCSS)-a multi-institution research initiative. Among these patients, a total of 679 secondary neoplasms were reported (419 of which were nonmelanoma skin cancers). In total, 196 malignant tumors were diagnosed in 180 patients.

Among the cohort, risk was found to be increased for breast cancer, soft-tissue sarcoma, renal cancer, and thyroid cancer.

The study found that a malignant neoplasm in these patients was not more likely among those patients had developed any neoplasm by the age of 40 (P = 0.35). But, both radiation exposure and a history of a subsequent neoplasm were factors associated with a greater risk of a secondary neoplasm after age 40 when compared to patients with neither (62.3% vs 13.3%).

Women and those exposed to radiation during treatment for their childhood cancer had the highest risk of a secondary cancer (P < .001 for both factors).

No increased risk for secondary cancers was seen in men aged 40 or older who had not been treated with radiotherapy, even if they had a history of a second neoplasm before age 40.

In a commentary accompanying the publication, Mark A. Applebaum, MD, and Susan L. Cohn, MD, both of the University of Chicago, highlighted that survivors of Hodgkin lymphoma, which is generally diagnosed in later childhood, make up a large proportion of the cohort and influenced the types of malignant tumors seen in adult patients. Patients who had childhood Hodgkin lymphoma comprise 30% of the CCSS and had a generally higher rate of neoplasms after the age of 40 (57%).

Women who had Hodgkin lymphoma as children are at higher risk for breast cancer into the 40s and 50s “warranting vigilant surveillance well beyond this age,” added the editorial authors.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content